COMBINED AMENDMENT & PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Small Entity)

Docket No. 55591(71699)

In Re Application Of: Jeffrey J. Rade, et al.

Serial No. 09/863,803

Filing Date May 22, 2001

Examiner Li, Qian J.

Group Art Unit

1632

Invention P AGENETIC ENGINEERING OF VASCULAR GRAFTS TO RESIST DISEASE

JAN 2 1 2003

RECEIVED

JAN 2 3 2003
TECH CENTER 1600/2900

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a combined amendment and petition t	under the provisions of 37 CFR 1.136(a) to extend the period for filling a
response to the Office Action ofAugust :	14, 2002 in the above-identified application.
	ate

The requested extension is as follows (check time period desired):

- ☐ One month
- ☐ Three months
- ☐ Four months
- ☐ Five months

from:

November 14, 2002 Date

until:

January 14, 2003 Date

A verified statement of small entity status as a small entity under 37 CFR 1.27:

- is enclosed.
- A has already been filed in this application.

The fee for the amendment and extension of time has been calculated as shown below:

CLAIMS AS AMENDED

	CLAIMS REMAINING		HIGHEST #		NUMBER EXTRA		RATE	ADDITIONAL
	AFTER AME	NDMENT	PREV. PAID FOR		CLAIMS PRESENT		KAIE	FEE
TOTAL CLAIMS	26	-	28	=	0	х	\$9.00	\$0.00
INDEP. CLAIMS	2	-	3	=	0	х	\$42.00	\$0.00
	\$0.00							
	\$205.00							

TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME

01/21/2003 BABRAHA1 00000039 09863803

01 Ft:2252

205.00 OP

\$205.00

COMBINED AMENDMENT & PETITION FOR EXTENSION OF TIME_UNDER 37 CFR 1.136(a) (Small Entity)

Docket No. 55591(71699)



The fee for the amendment and extension of time is to be paid as follows:

A check in the amount of

\$205.00

for the amendment and extension of time is enclosed.

Please charge Deposit Account No.

in the amount of \$205.00

A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. A duplicate copy of this sheet is enclosed.

- Any additional filing fees required under 37 C.F.R. 1.16.
- Any patent application processing fees under 37 CFR 1.17.

☑ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 04-1105 A duplicate copy of this sheet is enclosed.

Signature

R bert L. Buchanan (Registration No. 40,927) Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group of **EDWARDS & ANGELL, LLP** P. O. Box 9169, Boston, MA 02209

Tel. (617) 439-4444

Fax: (617) 439-4170 / 7748

Customer No.: 21874

Dated: 1476203

I certify that this document and fee is being deposited on 01/14/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Patricia A. Barnes

Typed or Printed Name of Person Mailing Correspondence

CC:





Docket No. 55591(71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jeffrey J. Rade, et al.

U.S.S.N.:

09/863,803

Art Unit:

1632

FILED:

May 22, 2001

Examiner:

Li, Qian J.

FOR:

GENETIC ENGINEERING OF VASCULAR GRAFTS TO RESIST DISEASE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on **January 14, 2003**.

Patricia A Barnes

RESPONSE UNDER 37 CFR 1.111

In response to the Office Action dated August 14, 2002 for the above-captioned case, Applicants request reconsideration in view of the following amendments and remarks. The period for response has been extended by the enclosed Petition For Extension of Time and requisite fee.

IN THE CLAIMS:

Please cancel claims 2/and 13.

Kindly amend claims 1, 7 and 24 as follows:

1. (Amended) A method for treating a vascular graft comprising,

6/

a) introducing into cells of the graft an effective amount of at least one nucleic acid encoding at least one of the following agents: endothelial cell